Q-omics provides the consensus-scored MIR3129 profile across patient tissues and cancer cell-line models. MIR3129 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR3129 is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, MIR3129 RNA expression shows 9,055 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, STAD, and LSCC as cancer lineages where MIR3129 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3129 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3129 survival associations across molecular data types. MIR3129 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3129 RNA expression–survival associations across cancer types. High MIR3129 expression shows unfavorable associations in KIRC, BRCA, LGG, MESO, SARC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR3129 RNA expression.
This table summarizes MIR3129 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3129. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3129 shows lower tumor expression in THCA and higher tumor expression in STAD and LUSC. The STAD box plot shows higher MIR3129 RNA expression in tumor versus normal tissue (log2 FC = +2.145, t-test p < 0.001).
This table shows molecular features associated with MIR3129 in patient tissues and cancer cell lines. In patient samples, MIR3129 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
